Atlas Venture Life Science Advisors LLC Has $142.40 Million Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

Atlas Venture Life Science Advisors LLC lowered its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 10.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,287,233 shares of the company’s stock after selling 267,939 shares during the quarter. Disc Medicine makes up 13.1% of Atlas Venture Life Science Advisors LLC’s investment portfolio, making the stock its 3rd largest position. Atlas Venture Life Science Advisors LLC owned about 9.47% of Disc Medicine worth $142,403,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Strs Ohio boosted its stake in Disc Medicine by 66.7% in the 4th quarter. Strs Ohio now owns 1,000 shares of the company’s stock worth $57,000 after purchasing an additional 400 shares during the period. AJOVista LLC bought a new position in Disc Medicine in the 4th quarter worth about $63,000. China Universal Asset Management Co. Ltd. bought a new position in Disc Medicine in the 4th quarter worth about $161,000. Simplicity Solutions LLC bought a new position in Disc Medicine in the 4th quarter worth about $215,000. Finally, Bleakley Financial Group LLC bought a new position in Disc Medicine in the 4th quarter worth about $215,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Up 2.4 %

Shares of NASDAQ IRON traded up $1.11 during trading hours on Thursday, reaching $46.91. 277,945 shares of the stock traded hands, compared to its average volume of 416,108. The company has a market capitalization of $1.16 billion, a P/E ratio of -13.88 and a beta of 0.57. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60. The company’s 50-day simple moving average is $38.31 and its two-hundred day simple moving average is $49.48.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). As a group, sell-side analysts forecast that Disc Medicine, Inc. will post -4.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Raymond James lifted their price target on Disc Medicine from $40.00 to $43.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Disc Medicine in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, May 28th. Morgan Stanley dropped their price target on Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. Finally, Wedbush reiterated an “outperform” rating and set a $57.00 price target (up previously from $43.00) on shares of Disc Medicine in a research report on Friday, June 14th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and an average target price of $62.57.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.